AKR.L Share News (AKR)
AKR Share
AKR Share
AKR Share
AKR Share
AKR
AKR Share
AKR Broker
AKR Directors
AKR Financial
AKR
AKR Short
AKRThu, 23rd Jan 2014 18:16
LONDON (Alliance News) - Akers Biosciences Inc said Thursday that its shares will recommence trading on AIM Friday, and announced the pricing of its public offering on the NASDAQ.
Akers Biosciences will offer 2.7 million shares at USD5.50 each, hoping to raise around USD15 million in gross proceeds.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @hanassallnews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
(ShareCast News) - Akers Biosciences has begun to make direct sales of its disposable breath ketone test, Metron, through the Amazon website and via the company's online sales portal. The medical device company said the Metron Breath Ketone Test, which is part of its health and wellness line, is the
Read more(ShareCast News) - Akers Biosciences plummeted after the medical device company said its pre-tax loss widened in the first half as revenue declined. Akers posted a pre-tax loss of $3.41m for the six months ended 30 June, wider than the $1.1m loss in the same period last year. This included a one-tim
Read more